NL-OMON37435尚未招募不适用
A randomized, double-blind, double-dummy, single dose, 4-way cross-over study to develop an anti-cholinergic pharmacological challenge with mecamylamine in comparison to scopolamine - Mecamylamine challenge in healthy volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Signed informed consent document
- •2. Healthy, male volunteers aged between 18 and 45 years
- •3. Body Mass Index between 18 kg/m2 and 32 kg/m2
- •4. Non-smokers for at least 1 year
- •5. Willingness to comply with study procedures and restrictions
排除标准
- •1. Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history taking and physical examinations obtained during the screening visit as judged by the investigator;
- •2. Clinically relevant abnormal laboratory results, electrocardiogram (ECG) and vital signs, or physical findings at screening (as judged by the investigator);
- •3. Presence of orthostatic hypotension as defined by a decrease of blood pressure >=10 mmHg systolic or >= 20 mmHg diastolic measured 2 min after standing up
- •4. Positive test for hepatitis B, C or HIV;
- •5. History of alcoholism or substance abuse within three years prior to screening;
- •6. Subjects unable to refrain from alcohol use from 24hours prior to dosing on Day 1 Periods 1-5 until discharge from the CRU for each study period;
- •7. Used tobacco and/or nicotine-containing products within one year of dosing on Day 1 Period 1;
- •8. Evidence of elevated blood pressure at screening of >140 mmHg systolic or >90 mmHg diastolic;
- •9. Subject is a habitual and heavy consumer of caffeinated beverages (more than 6 cups of coffee or equivalent/day) at screening and/or is not able to refrain from use of (methyl) xanthines (e.g. coffee, tea, cola, chocolate) from 12 hours prior to dosing until discharge from the CRU for each study period;
- •10. Positive urine drug screen (UDS) or alcohol or cotinine test at screening and/or Day 1 of each period;
- •11. Subject is unable to refrain from the use of concomitant medication which, in the opinion of the investigator, interferes with their ability to participate in the trial, from 7 days prior to dosing on Day 1 Period 1 until the follow-up study visit;
- •12. Subject has a history of severe allergies, or has had an anaphylactic reaction to prescription or non-prescription drugs or food;
- •13. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drugs (mecamylamine or scopolamine);
- •14. Currently using any nicotine replacement therapy, smoking cessation medications or remedies, including varenicline (Chantix ®) or have used any nicotinic products for smoking cessation within 3 months of screening; history of allergic reaction to nicotine-containing products
- •15. Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug (Day 1 Period 1) or more than 4 times per year;
- •16. Donation of blood/plasma outside limits of Sanquin Blood Supply Foundation guidelines of approximately 500 mL or significant blood loss;
- •17. Have a history of an allergic reaction to nicotine containing products;
- •18. Subject does not have veins suitable for canula placement on both arms;
- •19. Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject.
研究者
相似试验
已完成
不适用
Safety and Efficacy of Loxoprofen Sodium cataplasm Ointment Against Knee OsteoarthritisMusculoskeletal DiseasesGonarthrosis [arthrosis of knee]Knee osteoarthritisISRCTN40097939ead Chemical Co. Ltd (Japan)160
已完成
不适用
Safety and Efficacy of Loxoprofen Sodium cataplasm Ointment Against Swelling and Pain caused By Trauma (SELSOASPBT)ISRCTN10182003ead Chemical Co. Ltd (Japan)160
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, two-way cross-overstudy evaluating systemic bioavailability and airway clearance ofSymbicort® Turbuhaler® 320/9µg/inhalation versus Seretide™ Diskus™50/500µg/inhalation after single inhalations in patients with ChronicObstructive Pulmonary Disease (COPD) and healthy volunteers - Airway clearanceThis is a Clinical Pharmacology study to be conducted in one patient group with severe COPD and one group of healthy volunteers.MedDRA version: 14.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-002412-10-DEAstraZeneca AB54
已完成
2 期
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in nondiabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (CSPP100A2260, ARIA study)nondiabetic nephropathy10029149NL-OMON36542ovartis32
进行中（未招募）
不适用
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the Added effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (ARIA)EUCTR2009-012196-10-NLovartis Pharma Services AG32